Back to Search Start Over

Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3.

Authors :
Deokar H
Deokar M
Buolamwini JK
Source :
Molecular diversity [Mol Divers] 2024 Apr; Vol. 28 (2), pp. 497-507. Date of Electronic Publication: 2023 Jan 17.
Publication Year :
2024

Abstract

Fingerprint-based similarity searching is an important strategy for virtual screening in drug discovery. In the present study, we carried out a systematic virtual screening study, followed by the establishment of kernel-based partial least square (KPLS) analysis prediction models for five tyrosine kinase drug targets, C-terminal SRC kinase (CSK), human epidermal growth factor 2 (HER2), and Janus kinases 1, 2, and 3 (JAK1, JAK2, and JAK3), using a dataset of 3688 compounds. These kinases are important drug discovery targets, particularly as HER2 has been validated for the treatment of metastatic breast cancer, JAK inhibitors have been validated for the clinical management of arthritis and autoimmune diseases, and CSK has been found to play an important role in bone remodeling in arthritis. We conducted similarity screenings with the most active molecule for each target in the dataset as a query using eight (8) types of two-dimensional (2D) molecular fingerprints, comprising seven Hashed fingerprints, Linear, Dendritic, Radial, Pairwise, Triplet, Torsion, and MOLSPRINT2D, and one Structural keys fingerprint, MACCS. The top ranked 1% of compounds from each target's similarity screening results was used to set up kernel-based partial least square (KPLS) prediction models, with q <superscript>2</superscript> values up to 0.8. The best KPLS model for each target was selected based on its predictive ability and boot strapping results and used for prediction. This integrated study approach combining similarity screening with KPLS analysis has a high potential to enhance the accuracy and efficiency of virtual screening and thus improve the drug discovery process.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)

Details

Language :
English
ISSN :
1573-501X
Volume :
28
Issue :
2
Database :
MEDLINE
Journal :
Molecular diversity
Publication Type :
Academic Journal
Accession number :
36648693
Full Text :
https://doi.org/10.1007/s11030-022-10596-1